west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "靶向治疗" 83 results
  • Research Progress of Resistance Genes and Targeted Therapy for Gallbladder Carcinoma

    Objective To summarize the development of gallbladder carcinoma related resistance genes and targeted therapy. Methods Domestic and international publications online involving resistance genes and targeted therapy of gallbladder carcinoma in recent years were collected and reviewed. Results Recent studies had shown that chemotherapy drug resistance of gallbladder carcinoma mainly involved lysosome protein transmembrane β4 (LAPTM4B) gene, NF-E2-related factor 2 (Nrf2) gene, and cancer stem cells (CSCs). While the latest gene targets of treatment for gallbladder carcinoma mainly involved LAPTM4B, Nemo-like kinase (NLK), tissue factor way inhibitor-2 (TFPI-2), vascular endothelial growth factor-D (VEGF-D), epidermal growth factor receptor (EGFR), and melanoma differentiation-associated gene 7/interleukin 24 (mda-7/IL-24) gene. Conclusion The research involving resistance genes and targeted therapy of gallbladder carcinoma has make a certain progress, which broaden the concept of traditional treatment of gallbladder carcinoma.

    Release date: Export PDF Favorites Scan
  • PROGRESS OF OSTEOSARCOMA THERAPY

    Objective To review the research progress of the treatment of osteosarcoma, and to thoroughly understand its current state of research and prospect so as to lay a sol id foundation for the cl inical treatment. Methods The cl inical and experimental research l iteratures about treatment of osteosarcoma were extensively reviewed and analyzed. Results The present treatment of osteosarcoma is still need to comprehensive therapy which combine chemotherapy and surgical treatment. There are some progresses in gene therapy and molecular targeting therapy which can improve survival rate. Furthermore, well-designed studies and cl inical trials are needed to evaluate the potential therapeutic impact before they are used in cl inical. Conclusion Advancement in chemotherapeutic regimens has improved survival and l imb-sparing surgery in the treatment of osteosarcoma, but the progress of gene therapy and molecular targeting therapy gives new hope for osteosarcoma patients.

    Release date:2016-09-01 09:04 Export PDF Favorites Scan
  • Meta-analysis of Anti-Vascular Endothelial Growth Factor Agents Therapy for Advanced Renal Cell Carcinoma

    Objective To evaluate the efficacy and safety of anti-vascular endothelial growth factor (VEGF) agents for advanced renal cell carcinoma. Methods We searched MEDLINE, EMbase, The Cochrane Library, CBMdisc and China Academic Periodical database from the establishment of each database to April 2009. We included randomized controlled trials (RCTs) that evaluated anti-VEGF agents (sunitinib, sorafenib and bevacizumab). The quality of the included trials was evaluated by two reviewers independently. Meta-analyses were conducted by the Cochrane Collaboration’s RevMan 4.2 software. Results Four RCTs involving 2 320 patients were identified. According to the different interventions for advanced renal cell carcinoma, we divided the patients into two groups: anti-VEGF agents monotherapy and anti-VEGF agents plus interferon combination treatment. Our meta-analyses showed: monotherapy was superior to interferon on inhibition of tumor progression [OR=0.38, 95%CI (0.29, 0.51), Plt;0.01] and control of tumor [OR=2.53, 95%CI (1.87, 3.43), Plt;0.01], but was not significantly different from interferon on the overall effective rate [OR=1.97, 95%CI (0.20, 19.57), P=0.56] and serious side effects [OR=1.98, 95%CI (0.90, 4.34), P=0.09]. There were significant differences between anti-VEGF agents plus interferon and interferon alone on inhibition of tumor progression [OR=0.67, 95%CI (0.53, 0.84), P=0.000 5], overall effective rate [OR=2.65, 95%CI (1.94, 3.61), Plt;0.01], control of tumor [OR=2.14, 95%CI (1.65, 2.78), Plt;0.01] and serious side effects [OR=2.63, 95%CI (2.09, 3.31), Plt;0.01]. Conclusion Compared with interferon, anti-VEGF agents could inhibit tumor progression more effectively. Moreover, the combination therapy with interferon could offer a more favorable overall effective rate for advanced renal cell carcinoma, but then followed by more serious side effects. We need to weigh the merits and demerits of drugs before making a clinical decision for advanced renal cell carcinoma.

    Release date:2016-09-07 11:23 Export PDF Favorites Scan
  • 脑干胶质瘤的干细胞研究进展

    脑干胶质瘤是威胁人类健康的重要疾病,尤其是弥漫内生性桥脑胶质瘤,对儿童的影响更是致命性的。脑干胶质瘤占儿童后颅窝肿瘤的30%,而弥漫内生性桥脑胶质瘤占儿童脑肿瘤15%左右。后者其中位生存时间几乎不超过1年。由于过去在其生物学特性等方面研究欠缺导致此类肿瘤的治疗几乎无实质性进展。但随着近年脑干胶质瘤干细胞及其相关信号通路、细胞因子等方面的基础研究兴起,治疗方面取得了一定的成绩。在此,我们将就近几年在弥漫内生性桥脑胶质瘤基础方面的研究进展作相关综述及讨论。

    Release date:2016-09-07 02:34 Export PDF Favorites Scan
  • 头颈部癌的分子靶向治疗进展

    头颈部癌是耳鼻喉常见的肿瘤之一,经首次治疗后局部复发和发生远处转移往往预后较差。分子靶向治疗是以肿瘤细胞过度表达的某些标志性分子为靶点,选择具有针对性的阻断剂来干预受该标志性分子调控、并与肿瘤发生密切相关的信号转导通路,从而抑制肿瘤生长和转移。目前,分子靶向治疗逐渐成为研究热点,有望改善头颈部癌的治疗效果。本文就头颈部癌分子靶向治疗进行综述。

    Release date: Export PDF Favorites Scan
  • 多靶点酪氨酸激酶抑制剂的临床应用进展

    蛋白酪氨酸激酶介导的信号传导通路是目前研究较多且效果明显的抗肿瘤药物靶点,多靶点酪氨酸激酶抑制剂能够抑制多个信号传导通路,诱导肿瘤细胞的凋亡,阻断新生血管的生成,抑制肿瘤细胞的增殖,是近几年上市的主要抗肿瘤药物。现对多靶点酪氨酸激酶抑制剂的临床应用、注意事项及目前研究进展进行综述。

    Release date:2016-09-07 02:37 Export PDF Favorites Scan
  • 皮肤NK/T细胞淋巴瘤的治疗与研究现状

    结外鼻型NK/T细胞淋巴瘤(ENKTCL)是一种少见疾病,其分布具有明显的地域和种族特征,西方国家比较少见,多发生于亚洲、墨西哥及中南美洲,占所有非霍奇金淋巴瘤的5%~18%。按解剖部位被划分为上呼吸消化道NK/T细胞淋巴瘤(UAT-NKTCL)和非上呼吸消化道NK/T细胞淋巴瘤(NUAT-NKTCL)。在非上呼吸消化道病例中,皮肤往往是瘤体最常侵犯的器官。皮肤受累的结外鼻型NK/T细胞淋巴瘤称为皮肤NK/T细胞淋巴瘤(CNKTCL),包括了原发于皮肤以及原发于皮肤外的晚期ENKTCL皮肤浸润,但是不论是疾病原发或是继发的晚期皮肤浸润,其病程进展快,预后差,中位生存时间<12个月。侵袭性淋巴瘤常用的化学疗法方案如CHOP(环磷酰胺+多柔比星+长春新碱+泼尼松)或者CHOP类似方案以及对鼻部早期患者证实有效的局部放射治疗在皮肤NK/T患者中并未带来明显的生存获益,目前新的治疗方案还在探索中。随着肿瘤分子生物学的标靶干预和基因组研究的深入进展,靶向治疗有望为CNKTCL患者带来福音。本文将着重就CNKTCL治疗现状和预后加以综述。

    Release date:2016-09-08 09:11 Export PDF Favorites Scan
  • 食管癌的分子靶向治疗研究进展

    近年来,手术及放射、化学疗法在食管癌治疗方面取得了一定的进步,然而对食管癌患者并没有带来长期生存率的明显增高。分子靶向治疗在食管癌的应用逐渐受到越来越多的关注。目前,已有众多Ⅰ/Ⅱ期临床试验用于评估食管癌分子靶向治疗疗效。

    Release date:2016-09-08 09:11 Export PDF Favorites Scan
  • 表皮生长因子受体单克隆抗体耐药机制研究的新进展

    表皮生长因子受体(EGFR)是HER家族中一类表皮生长因子酪氨酸激酶受体,其下游的信号通路调控着细胞的生长、增殖、分化、侵袭、迁移、血管形成等生物学行为。EGFR在上皮源性肿瘤中常有表达,在近几十年中,将EGFR作为抗肿瘤治疗的靶点,研制出一系列靶向治疗药物,主要有小分子酪氨酸激酶抑制剂和单克隆抗体这两大类。然而,在结直肠癌中EGFR单克隆抗体靶向治疗的有效率却不高,原发和继发性耐药成为阻碍靶向药物应用的关键因素。由此推动了关于靶向药物各种耐药机制的研究,现就近两年来EGFR单克隆抗体耐药机制研究的新进展作一综述。

    Release date:2016-09-07 02:38 Export PDF Favorites Scan
  • 成纤维细胞活化蛋白在上皮癌中表达的意义及研究进展

    【摘要】 成纤维细胞活化蛋白(fibroblast activation protein,FAP)广泛存在于上皮癌组织中,在肿瘤间质成纤维细胞选择性表达而在正常的成熟组织中几乎不表达,是上皮癌的特异性靶标。FAP具有蛋白酶活性,并且可与其他细胞表面蛋白分子形成复合物,可能作用于细胞信号传导,参与肿瘤间质重塑和血管网的形成,调节肿瘤细胞的生长、分化、黏附和转移。目前,有许多临床前期实验及临床研究报导,靶向FAP能有效抑制上皮癌的生长和转移。FAP将可能成为治疗上皮癌的新靶点。现综述总结了FAP的生物学特性,其表达对上皮癌发生发展的影响,以及靶向FAP的抗肿瘤研究进展。

    Release date:2016-09-08 09:26 Export PDF Favorites Scan
9 pages Previous 1 2 3 ... 9 Next

Format

Content